Cyclodextrins in non-viral gene delivery

Biomaterials

Volumn 35, Issue 1, 2014, Pages 401-411

  Lai, Wing Fu ^a  

^a Yonsei University College of Dentistry   (South Korea)

Author keywords

Cyclodextrin; Gene delivery; Non viral vector; Polymer; Transfection

Indexed keywords

AMPHIPHILIC CHARACTER; APPLICATION PROSPECT; CONTROLLED DRUG RELEASE; CYCLIC OLIGOSACCHARIDES; GENE DELIVERY; NON-VIRAL GENE DELIVERY; NONVIRAL VECTORS; TRANSFECTION;

CYCLODEXTRINS; DRUG DELIVERY; POLYMERS;

GENE TRANSFER;

ALPHA CYCLODEXTRIN; BENEXATE; BETA CYCLODEXTRIN; CEFOTIAM; CEFOTIAM HEXETIL; CYCLODEXTRIN; DEXAMETHASONE; FENTIAZAC; GAMMA CYCLODEXTRIN; GLYCERYL TRINITRATE; GLYMESASON; IODINE; LIMAPROST; LIPOSOME; MENA GARGLE; NICOGUM; NICOTINE; NICOTINE GUM; NIMEDEX; NIMESULIDE; OMEBETA; OMEPRAZOLE; OPALMON; PIROXICAM; PIROXICAM BETA CYCLODEXTRIN; POLY[2 (DIMETHYLAMINO)ETHYL METHACRYLATE]; POLYAMIDOAMINE; POLYMER; PRORENAL; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAVASIN; PROSTAVASTIN; RIGIDUR; TIAPROFENIC ACID; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; COMPLEX FORMATION; CRITICAL LIMB ISCHEMIA; DRUG FORMULATION; DYSPEPSIA; ENDOCYTOSIS; ERECTILE DYSFUNCTION; GASTROESOPHAGEAL REFLUX; GENE; GENETIC TRANSFECTION; HEART FAILURE; HUMAN; IMMUNOSTIMULATION; LARYNGOPHARYNGEAL REFLUX; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATENT DUCTUS ARTERIOSUS; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; STOMACH ULCER; THROMBOCYTE AGGREGATION; VIRUS INHIBITION; ZOLLINGER ELLISON SYNDROME;

CYCLODEXTRIN; GENE DELIVERY; NON-VIRAL VECTOR; POLYMER; TRANSFECTION;

CYCLODEXTRINS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS;

EID: 84887018444     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.061     Document Type: Review

References (111)

1. Del Valle E.M.M. Cyclodextrins and their uses: a review. Process Biochem 2004, 39:1033-1046.
2. Villiers A. Sur la fermentation de la fécule par l'action du ferment butyrique. Compt Rendus Acad Sci 1891, 112:536-538.
3. Freudenberg K., Meyer-Delius M. Über die Schardinger-Dextrine aus Stärke. Ber dtsch Chem Ges A/B 1938, 71:1596-1600.
4. Freudenberg K., Schaaf E., Dumpert G., Ploetz T. Neue Ansichten über die Stärke. Naturwissenschaften 1939, 51:850-853.
5. Cramer F. Einschlussverbindungen 1954, Springer-Verlag, Berlin.
6. Bechet I., Paques P., Fillet M., Hubert P., Crommen J. Chiral separation of basic drugs by capillary zone electrophoresis with cyclodextrin additives. Electrophoresis 1994, 15:818-823.
7. He H., Chen S., Zhou J., Dou Y., Song L., Che L., et al. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials 2013, 34:5344-5358.
8. Lepretre S., Chai F., Hornez J.C., Vermet G., Neut C., Descamps M., et al. Prolonged local antibiotics delivery from hydroxyapatite functionalised with cyclodextrin polymers. Biomaterials 2009, 30:6086-6093.
9. Fundueanu G., Constantin M., Dalpiaz A., Bortolotti F., Cortesi R., Ascenzi P., et al. Preparation and characterization of starch/cyclodextrin bioadhesive microspheres as platform for nasal administration of gabexate mesylate (Foy) in allergic rhinitis treatment. Biomaterials 2004, 25:159-170.
10. Quaglia F., Ostacolo L., Mazzaglia A., Villari V., Zaccaria D., Sciortino M.T. The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials 2009, 30:374-382.
11. Thatiparti T.R., Shoffstall A.J., von Recum H.A. Cyclodextrin-based device coatings for affinity-based release of antibiotics. Biomaterials 2010, 31:2335-2347.
12. Liu Y.Y., Fan X.D. Synthesis, properties and controlled release behaviors of hydrogel networks using cyclodextrin as pendant groups. Biomaterials 2005, 26:6367-6374.
13. Loftsson T., Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007, 329:1-11.
14. Kettel M.J., Dierkes F., Schaefer K., Moeller M., Pich A. Aqueous nanogels modified with cyclodextrin. Polymer 2011, 52:1917-1924.
15. Loftsson T., Brewster M.E., Másson M. Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv 2004, 2:261-275.
16. Szejtli J. Past, present and future of cyclodextrin research. Pure Appl Chem 2004, 76:1825-1845.
17. Redenti E., Pietra C., Gerloczy A., Szente L. Cyclodextrins in oligonucleotide delivery. Adv Drug Deliv Rev 2001, 53:235-244.
18. Dass C.R. Vehicles for oligonucleotide delivery to tumours. JPharm Pharmacol 2002, 54:3-27.
19. Habus I., Zhao Q., Agrawal S. Synthesis, hybridization properties, nuclease stability, and cellular uptake of the oligonucleotide-amino-β-cyclodextrins and adamantane conjugates. Bioconjug Chem 1995, 6:327-331.
20. Zhao Q., Temsamani J., Agrawal S. Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery. Antisense Res Dev 1995, 5:185-192.
21. Zhao Q., Temsamani J., Iadarola P.L., Agrawal S. Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. Biochem Pharmacol 1996, 52:1537-1544.
22. Abdou S., Collomb J., Sallas F., Marsura A., Finance C. Beta-Cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence. Arch Virol 1997, 142:1585-1602.
23. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009, 6:659-668.
24. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004, 3:1023-1035.
25. Forrest M.L., Gabrielson N., Pack D.W. Cyclodextrin-polyethylenimine conjugates for targeted invitro gene delivery. Biotechnol Bioeng 2005, 89:416-423.
26. Pun S.H., Bellocq N.C., Liu A., Jensen G., Machemer T., Quijano E., et al. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug Chem 2004, 15:831-840.
27. Gonzalez H., Hwang S.J., Davis M.E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug Chem 1999, 10:1068-1074.
28. Freeman D.J., Niven R.W. The influence of sodium glycocholate and other additives on the invivo transfection of plasmid DNA in the lungs. Pharm Res 1996, 13:202-209.
29. Formoso C. The interaction of β-cyclodextrin with nucleic acid monomer units. Biochem Biophys Res Commun 1973, 50:999-1005.
30. Hwang S.J., Bellocq N.C., Davis M.E. Effects of structure of β-cyclodextrin-containing polymers on gene delivery. Bioconjug Chem 2001, 12:280-290.
31. Martins P.S., Ochoa R., Pimenta A.M., Ferreira L.A., Melo A.L., da Silva J.B., et al. Mode of action of β-cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate. Int J Pharm 2006, 325:39-47.
32. Schipper N.G., Verhoef J.C., De Lannoy L.M., Romeijn S.G., Brakkee J.H., Wiegant V.M., et al. Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-β-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics. Br J Pharmacol 1993, 110:1335-1340.
33. Croyle M.A., Roessler B.J., Hsu C.P., Sun R., Amidon G.L. Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharm Res 1998, 15:1348-1355.
34. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46:3-26.
35. Loftsson T., Jarho P., Masson M., Jarvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005, 2:335-351.
36. Irie T., Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. JPharm Sci 1997, 86:147-162.
37. Matsuda H., Arima H. Cyclodextrins in transdermal and rectal delivery. Adv Drug Deliv Rev 1999, 36:81-99.
38. Zidovetzki R., Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta 2007, 1768:1311-1324.
39. Grunze M., Deuticke B. Changes of membrane permeability due to extensive cholesterol depletion in mammalian erythrocytes. Biochim Biophys Acta 1974, 356:125-130.
40. Cryan S.A., Holohan A., Donohue R., Darcy R., O'Driscoll C.M. Cell transfection with polycationic cyclodextrin vectors. Eur J Pharm Sci 2004, 21:625-633.
41. Ortega-Caballero F., Mellet C.O., Le Gourrierec L., Guilloteau N., Di Giorgio C., Vierling P., et al. Tailoring β-cyclodextrin for DNA complexation and delivery by homogeneous functionalization at the secondary face. Org Lett 2008, 10:5143-5146.
42. Diaz-Moscoso A., Balbuena P., Gomez-Garcia M., Ortiz Mellet C., Benito J.M., Le Gourrierec L., et al. Rational design of cationic cyclooligosaccharides as efficient gene delivery systems. Chem Commun (Camb) 2008, 2001-2003.
43. Diaz-Moscoso A., Le Gourrierec L., Gomez-Garcia M., Benito J.M., Balbuena P., Ortega-Caballero F., et al. Polycationic amphiphilic cyclodextrins for gene delivery: synthesis and effect of structural modifications on plasmid DNA complex stability, cytotoxicity, and gene expression. Chemistry 2009, 15:12871-12888.
44. Mendez-Ardoy A., Gomez-Garcia M., Ortiz Mellet C., Sevillano N., Giron M.D., Salto R., et al. Preorganized macromolecular gene delivery systems: amphiphilic β-cyclodextrin "click clusters". Org Biomol Chem 2009, 7:2681-2684.
45. García Fernández J.M., Benito J.M., Mellet C.O. Cyclodextrin-scaffolded glycotransporters for gene delivery. Pure Appl Chem 2013, 85:1825-1845.
46. Neu M., Fischer D., Kissel T. Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. JGene Med 2005, 7:992-1009.
47. Davis M.E., Pun S.H., Bellocq N.C., Reineke T.M., Popielarski S.R., Mishra S., et al. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr Med Chem 2004, 11:179-197.
48. Liang B., Deng J.J., Yuan F., Yang N., Li W., Yin J.R., et al. Efficient gene transfection in the neurotypic cells by star-shaped polymer consisting of β-cyclodextrin core and poly(amidoamine) dendron arms. Carbohydr Polym 2013, 94:185-192.
49. Zhao F., Yin H., Zhang Z., Li J. Folic acid modified cationic γ-cyclodextrin-oligoethylenimine star polymer with bioreducible disulfide linker for efficient targeted gene delivery. Biomacromolecules 2013, 14:476-484.
50. Ma D., Zhang H.B., Chen Y.Y., Lin J.T., Zhang L.M. New cyclodextrin derivative containing poly(L-lysine) dendrons for gene and drug co-delivery. JColloid Interface Sci 2013, 405:305-311.
51. Xu F.J., Zhang Z.X., Ping Y., Li J., Kang E.T., Neoh K.G. Star-shaped cationic polymers by atom transfer radical polymerization from β-cyclodextrin cores for nonviral gene delivery. Biomacromolecules 2009, 10:285-293.
52. Yang C., Li H., Goh S.H., Li J. Cationic star polymers consisting of α-cyclodextrin core and oligoethylenimine arms as nonviral gene delivery vectors. Biomaterials 2007, 28:3245-3254.
53. Huang H., Tang G., Wang Q., Li D., Shen F., Zhou J., et al. Two novel non-viral gene delivery vectors: low molecular weight polyethylenimine cross-linked by (2-hydroxypropyl)-β-cyclodextrin or (2-hydroxypropyl)-γ-cyclodextrin. Chem Commun (Camb) 2006, 2382-2384.
54. Ren L.L., Wu Y., Han D., Zhao L.D., Sun Q.M., Guo W.W., et al. Math1 gene transfer based on the delivery system of quaternized chitosan/Na-carboxymethyl-β-cyclodextrin nanoparticles. JNanosci Nanotechnol 2010, 10:7262-7265.
55. Hu Y., Tang G., Liu J., Cheng W., Yue Y., Li J., et al. FGF receptor-mediated gene delivery using ligands coupled to PEI-β-CyD. JBiomed Biotechnol 2012, 2012:989235.
56. Calzolari A., Oliviero I., Deaglio S., Mariani G., Biffoni M., Sposi N.M., et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis 2007, 39:82-91.
57. Bellocq N.C., Pun S.H., Jensen G.S., Davis M.E. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 2003, 14:1122-1132.
58. Yang C., Wang X., Li H., Goh S.H., Li J. Synthesis and characterization of polyrotaxanes consisting of cationic α-cyclodextrins threaded on poly[(ethylene oxide)-ran-(propylene oxide)] as gene carriers. Biomacromolecules 2007, 8:3365-3374.
59. Arima H., Kihara F., Hirayama F., Uekama K. Enhancement of gene expression by polyamidoamine dendrimer conjugates with α-, β-, and γ-cyclodextrins. Bioconjug Chem 2001, 12:476-484.
60. Wada K., Arima H., Tsutsumi T., Hirayama F., Uekama K. Enhancing effects of galactosylated dendrimer/α-cyclodextrin conjugates on gene transfer efficiency. Biol Pharm Bull 2005, 28:500-505.
61. Wada K., Arima H., Tsutsumi T., Chihara Y., Hattori K., Hirayama F., et al. Improvement of gene delivery mediated by mannosylated dendrimer/α-cyclodextrin conjugates. JControl Release 2005, 104:397-413.
62. Kihara F., Arima H., Tsutsumi T., Hirayama F., Uekama K. Effects of structure of polyamidoamine dendrimer on gene transfer efficiency of the dendrimer conjugate with α-cyclodextrin. Bioconjug Chem 2002, 13:1211-1219.
63. Kihara F., Arima H., Tsutsumi T., Hirayama F., Uekama K. Invitro and invivo gene transfer by an optimized α-cyclodextrin conjugate with polyamidoamine dendrimer. Bioconjug Chem 2003, 14:342-350.
64. Arima H., Arizono M., Higashi T., Yoshimatsu A., Ikeda H., Motoyama K., et al. Potential use of folate-polyethylene glycol (PEG)-appended dendrimer (G3) conjugate with α-cyclodextrin as DNA carriers to tumor cells. Cancer Gene Ther 2012, 19:358-366.
65. Elnakat H., Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004, 56:1067-1084.
66. Elwood P.C. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. JBiol Chem 1989, 264:14893-14901.
67. Theti D.S., Jackman A.L. The role of α-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res 2004, 10:1080-1089.
68. Toffoli G., Bevilacqua C., Franceschin A., Boiocchi M. Effect of hyperthermia onintracellular drug accumulation and chemosensitivity in drug-sensitive and drug-resistant P388 leukaemia cell lines. Int J Hyperthermia 1989, 5:163-172.
69. Motoyama K., Hayashida K., Higashi T., Arima H. Polypseudorotaxanes of pegylated α-cyclodextrin/polyamidoamine dendrimer conjugate with cyclodextrins as a sustained release system for DNA. Bioorg Med Chem 2012, 20:1425-1433.
70. Dandekar P., Jain R., Keil M., Loretz B., Muijs L., Schneider M., et al. Cellular delivery of polynucleotides by cationic cyclodextrin polyrotaxanes. JControl Release 2012, 164:387-393.
71. Anno T., Higashi T., Motoyama K., Hirayama F., Uekama K., Arima H. Potential use of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate (G2) as a DNA carrier invitro and invivo. JDrug Target 2012, 20:272-280.
72. Anno T., Higashi T., Motoyama K., Hirayama F., Uekama K., Arima H. Possible enhancing mechanisms for gene transfer activity of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate. Int J Pharm 2012, 426:239-247.
73. Arima H., Yamashita S., Mori Y., Hayashi Y., Motoyama K., Hattori K., et al. Invitro and invivo gene delivery mediated by lactosylated dendrimer/α-cyclodextrin conjugates (G2) into hepatocytes. JControl Release 2010, 146:106-117.
74. Chen Y., Zhou L., Pang Y., Huang W., Qiu F., Jiang X., et al. Photoluminescent hyperbranched poly(amido amine) containing β-cyclodextrin as a nonviral gene delivery vector. Bioconjug Chem 2011, 22:1162-1170.
75. Yamashita A., Choi H.S., Ooya T., Yui N., Akita H., Kogure K., et al. Improved cell viability of linear polyethylenimine through γ-cyclodextrin inclusion for effective gene delivery. Chembiochem 2006, 7:297-302.
76. Choi H.S., Yamashita A., Ooya T., Yui N., Akita H., Kogure K., et al. Sunflower-shaped cyclodextrin-conjugated poly(epsilon-lysine) polyplex as a controlled intracellular trafficking device. Chembiochem 2005, 6:1986-1990.
77. Hu Q.D., Fan H., Lou W.J., Wang Q.Q., Tang G.P. Polyethylenimine-cyclodextrin-tegafur conjugate shows anti-cancer activity and a potential for gene delivery. JZhejiang Univ Sci B 2011, 12:720-729.
78. Lu X., Ping Y., Xu F.J., Li Z.H., Wang Q.Q., Chen J.H., et al. Bifunctional conjugates comprising β-cyclodextrin, polyethylenimine, and 5-fluoro-2'-deoxyuridine for drug delivery and gene transfer. Bioconjug Chem 2010, 21:1855-1863.
79. Hu X., Wang N., Liu L., Liu W. Cyclodextrin-cross-linked diaminotriazine-based hydrogen bonding strengthened hydrogels for drug and reverse gene delivery. JBiomater Sci Polym Ed 2013.
80. Lai W.F., Tang G.P., Wang X., Li G., Yao H., Shen Z., et al. Cyclodextrin-PEI-Tat polymer as a vector for plasmid DNA delivery to placenta mesenchymal stem cells. Bionanoscience 2011, 1:89-96.
81. Tang Y.L., Zhao Q., Zhang Y.C., Cheng L., Liu M., Shi J., et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 2004, 117:3-10.
82. Meinel L., Hofmann S., Betz O., Fajardo R., Merkle H.P., Langer R., et al. Osteogenesis by human mesenchymal stem cells cultured on silk biomaterials: comparison of adenovirus mediated gene transfer and protein delivery of BMP-2. Biomaterials 2006, 27:4993-5002.
83. Ferreira E., Potier E., Logeart-Avramoglou D., Salomskaite-Davalgiene S., Mir L.M., Petite H. Optimization of a gene electrotransfer method for mesenchymal stem cell transfection. Gene Ther 2008, 15:537-544.
84. Chaturvedi K., Ganguly K., Kulkarni A.R., Kulkarni V.H., Nadagouda M.N., Rudzinski W.E., et al. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review. Expert Opin Drug Deliv 2011, 8:1455-1468.
85. Lai W.F., Lin M.C. Nucleic acid delivery with chitosan and its derivatives. JControl Release 2009, 134:158-168.
86. Arima H., Yoshimatsu A., Ikeda H., Ohyama A., Motoyama K., Higashi T., et al. Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. Mol Pharm 2012, 9:2591-2604.
87. Folini M., Pennati M., Zaffaroni N. RNA interference-mediated validation of genes involved in telomere maintenance and evasion of apoptosis as cancer therapeutic targets. Methods Mol Biol 2009, 487:303-330.
88. Day T.W., Safa A.R. RNA interference in cancer: targeting the anti-apoptotic protein c-FLIP for drug discovery. Mini Rev Med Chem 2009, 9:741-748.
89. Lai W.F. RNAi-mediated RNA degradation: future prospects of longevity enhancement. Advances in genetics research 2011, 369-378. Nova Publishers, New York. K.V. Urbano (Ed.).
90. Freudenberg K., Cramer F., Plieninger H. Verfahren zur Herstellung von Einschluβverbindungen physiologisch wirksamer organischer Verbindungen 1953, 895769.
91. Cramer F. Introduction. Cyclodextrins and their industrial uses 1987, 11-18. Éditions de Santé, Paris. D. Duchêne (Ed.).
92. French D. The Schardinger dextrins. Adv Carbohydr Chem 1957, 12:189-260.
93. Szejtli J. Cyclodextrin technology 1988, Kluwer Academic Publishers, Boston, MA.
94. Agrawal S., Habus I., Zhao Q.Y. Cyclodextrin cellular delivery system for oligonucleotides 1999, EP 0762898 B1.
95. Freeman D.J., Niven R. Formulations for non-viral invivo transfection in the lungs 2000, US 6022737 A.
96. Davis M.E., Gonzales H., Hwang S.S.J. Linear cyclodextrin copolymers 2003, US 6509323 B1.
97. Davis M.E., Gonzales H., Hwang S.S.J. Linear cyclodextrin copolymers 2005, US 6884789 B2.
98. Davis M.E., Gonzales H., Hwang S.S.J. Linear cyclodextrin copolymers 2006, US 7091192 B1.
99. Gonzales H., Hwang S.S.J., Davis M.E. Linear cyclodextrin copolymers 2007, EP 1093469 B1.
100. Davis M.E., Gonzales H., Hwang S. Method for preparing linear cyclodextrin copolymers 2013, EP 1764112 B1.
101. Hwang S.S.J., Bellocq N.C., Davis M.E. Cyclodextrin-based materials, compositions and uses related thereto 2013, US 8357377 B2.
102. Lai W.F. Nucleic acid delivery: roles in biogerontological interventions. Ageing Res Rev 2013, 12:310-315.
103. Lai W.F. Protein kinases as targets for interventive biogerontology: overview and perspectives. Exp Gerontol 2012, 47:290-294.
104. Lai W.F. Nucleic acid therapy for lifespan prolongation: present and future. JBiosci 2011, 36:725-729.
105. Lai W.F. Delivery of therapeutics: current status and its relevance to regenerative innovations. Recent Patent Nanomed 2011, 1:7-18.
106. Klausner E.A., Zhang Z., Wong S.P., Chapman R.L., Volin M.V., Harbottle R.P. Corneal gene delivery: chitosan oligomer as a carrier of CpG rich, CpG free or S/MAR plasmid DNA. JGene Med 2012, 14:100-108.
107. Cheng W., Yang C., Hedrick J.L., Williams D.F., Yang Y.Y., Ashton-Rickardt P.G. Deliverydified PEI protects against cytotoxic lymphocyte killing of a granzyme B inhibitor gene using carbamate-mannose mo. Biomaterials 2013, 34:3697-3705.
108. Newland B., Abu-Rub M., Naughton M., Zheng Y., Pinoncely A.V., Collin E., et al. GDNF gene delivery via a 2-(dimethylamino)ethyl methacrylate based cyclized knot polymer for neuronal cell applications. ACS Chem Neurosci 2013, 4:540-546.
109. Nam H.Y., Nam K., Lee M., Kim S.W., Bull D.A. Dendrimer type bio-reducible polymer for efficient gene delivery. JControl Release 2012, 160:592-600.
110. Lai W.F. Invivo nucleic acid delivery with PEI and its derivatives: current status and perspectives. Expert Rev Med Dev 2011, 8:173-185.
111. Lai W.F., Lin M.C.M. Synthesis and properties of chitosan-PEI graft copolymers as vectors for nucleic acid delivery. JMater Sci Eng 2010, 4:34-41.